Dr Richard Weaver
Joined Sygnature in September 2020 as SVP, Preclinical Development.
Richard has over 25 years’ experience in the drug discovery industry from medicinal chemistry to DMPK and preclinical development. In that time he has gained and developed an in-depth knowledge of all aspects of in vitro and in vivo DMPK, from hit identification to candidate drug nomination and beyond from his experience at AstraZeneca. After leaving AstraZeneca, Richard set up XenoGesis in 2011, which grew to be the UK’s largest independent DMPK provider, before becoming part of Sygnature Discovery in 2020.
Richard has a BA and a DPhil in medicinal chemistry from the University of Leicester, and undertook post-doctoral research at the Welsh School of Pharmacy.